BREAKING🔔 We introduce the latest work from G2P-Japan🇯🇵 focusing on the virological characteristics of new SARS-CoV-2 lineage of concern, XBB.1.5 (aka #Kraken), which is rapidly spreading in the US🇺🇸 Please RT! Preprint/peer-review paper will come soon🔥 1/
XBB.1.5 = XBB.1 + #F486P in spike. We also found that a part of XBB.1.5 has reversion mutation in Y144del (=XBB.1.5 + #ins144Y) in spike. Because #Y144del evades antiviral immunity and decreases pseudovirus infectivity, its reversion might be also critical. 2/
First, a brilliant young talent, @jampei2, showed that the relative basic reproduction number (Re) of XBB.1.5 is >1.2-fold greater than the parental XBB.1 (❗️). Importantly the "1.2-fold difference" is similar to the differences between BA.1 versus BA.2 and BA.2 versus BA.5. 3/
We then showed that the KD value of XBB.1.5 spike is greatly lower than that of XBB.1 spike, meaning that XBB.1.5 spike exhibits very strong affinity to human ACE2, which is attributed to #F486P mutation. 4/
Experiments using pseudovirues also showed the ~3-fold increase of infectivity by #F486P mutation (XBB.1 << XBB.1.5). On the other hand, #ins144Y increased the infectivity of XBB.1 (XBB.1 < XBB.1+ins144Y) but did not increase that of XBB.1.5 (XBB.1.5 = XBB.1.5+ins144Y). 5/
Neutralization assay showed that XBB.1.5 is robustly (41-fold vs B.1.1, 20-fold vs BA.2) resistant to BA.2 breakthru infection sera. XBB.1.5 is also severely (32-fold vs B.1.1, 9.5-fold vs BA.5) resistant to BA.5 breakthru infection sera. 6/
BREAKING🔔 A new study from G2P-Japan🇯🇵, led by Keiya @Keiya717, is out at @biorxivpreprint. We assessed the humoral immunity induced by JN.1 mRNA vaccines against a broad range of SARS-CoV-2 variants including JN.1, KP.3.1.1 & XEC. Please repost🔥 1/ biorxiv.org/content/10.110…
In this study, we used 2 mRNA vaccines, one is from Pfizer/BioNTech🇺🇸🇩🇪, while another is from Daiichi-Sankyo🇯🇵. The good news is that there are no significant differences between them and both broadly neutralized a variety of SARS-CoV-2 including JN.1, KP.3.1.1 and XEC. 2/
But there are two scientific interests.
First, compared to our recent study using JN.1 and KP.3.3 breakthrough (i.e. natural) infection sera, antiviral humoral immunity against KP.3 and XEC was weakly induced. However, JN.1 mNRA vaccine can. Why🤔?? 3/
BREAKING🔔 A new study from G2P-Japan🇯🇵, led by Yu in my lab, is out at bioRxiv @biorxivpreprint. We elucidated the virological characteristics of SARS-CoV-2 #XEC. Please repost🔥 1/ biorxiv.org/content/10.110…
Compared with KP.3, #XEC harbors two spike substitutions, S:T22N and S:F59S. Recombination analysis by Shusuke @KawakuboShusuke showed that XEC is a recombinant lineage of KS.1.1 (JN.13.1.1.1) and KP.3.3 (JN.1.11.1.3.3) with a breakpoint at genomic position 21,738–22,599. 2/
Transmissibility/fitness (Re):
Molecular phylogenetic-epidemic dynamics modeling led by Jumpei @jampei2 and Kaho showed that the Re of #XEC is greater than that of KP.3.1.1, the most predominant variant in the world. 3/
BREAKING🔔 Here I want to quickly report our new results from G2P-Japan🇯🇵 before the preprint publication. We have elucidated the virological characteristics of SARS-CoV-2 KP.3.1.1 - a progeny of JN.1. Please RT🔥 1/
Cf.1 A new one, KP.2 (JN.1.11.1.2), has been already elucidated. 2/